Document:

SUPPLY AGREEMENT

         THIS AGREEMENT is made and entered into effective as of January 25,
2000, by and between Guidant Corporation and its affiliates ("Guidant") having a
place of business at 1525 O'Brien Drive, Menlo Park, California 94025 and
Everest Medical Corporation ("Everest") having a principal place of business at
13755 First Avenue North, Minneapolis, Minnesota 55441-5454.

                                    RECITALS

         A. Guidant is engaged in the discovery, development, manufacture and
sale of medical devices and has interests in the field of advanced diagnostic
and therapeutic medical systems; and

         B. Guidant desires to contract with Everest to develop, manufacture and
supply the Product (as defined below), and Everest is agreeable to doing so.

         In consideration of the terms and provisions of this Agreement, Everest
and Guidant hereby agree as follows:

         1. DEFINITIONS. Certain capitalized terms used in this Agreement are
defined below. Other capitalized terms are defined elsewhere in this Agreement.

         (a) "Act" shall mean the United States Food, Drug and Cosmetic Act of
1938, as amended, as well as all regulations promulgated thereunder.

         (b) "CE Mark" shall mean the CE Marking of conformity as prescribed by
Article 17 of Council Directive 93/42/EEC by the Council Of The European
Communities.

         (c) "Confidential Information" shall mean any information of a
confidential and/or proprietary nature as to which Everest or Guidant has
acquired or, during the term of this Agreement, acquires, any interest,
including, but not limited to, all discoveries, inventions, improvements and
ideas related to any process, method, formula, machine, device, manufacture,
composition of matter, plan or design, whether patentable or not, or relating to
the conduct of business by either of them, which, prior to the date hereof or
during the term of this Agreement, was or is disclosed to the other.
Notwithstanding the foregoing, the term Confidential Information shall not
include any information which: (i) has been published or otherwise becomes a
matter of public knowledge by any means other than the recipient's default in
the observance or performance of any term or provision of this Agreement or any
other obligation on its part to be observed and performed; (ii) was known to the
recipient at the time of such disclosure without a requirement of
confidentiality as evidenced by its written business records; (iii) is at any
time disclosed to the recipient by any person or entity not a party hereto whom
it believes, after reasonable inquiry, has the right to so disclose the same;
(iv) is required to be disclosed in compliance with any law governmental
regulation, or court order, provided that the recipient shall notify the

<PAGE>

disclosing party in advance of any such disclosure, if feasible; (v) is
developed independently of the information provided by the disclosing party.
Notwithstanding anything contained in this Agreement to the contrary,
Confidential Information will include any and all specifications (design,
process or performance) for the Product as well as any changes in those
specifications, and any and all sales and marketing information related to the
Product. Shared information deemed "Confidential" shall be in writing and
documented as "Confidential", provided, however, that any and all specifications
(design, process or performance) for the Product, and any and all sales and
marketing information related to the Product, shall be deemed "Confidential
Information" regardless of whether they are so designated in writing.

         (d) "Field" shall mean cardiac and vascular surgery.

         (e) "FDA" shall mean the United States Food and Drug Administration.

         (f) "Products" or "Product" shall mean the products which are listed
and more particularly described on Exhibit A hereto, which Exhibit is
incorporated into this Agreement by this reference.

         (g) "Territory" shall mean the whole world.

         2. MANUFACTURING OF PRODUCTS.

         (a) Warranties. Everest represents and warrants that the Products
delivered and sold to Guidant (i) shall be manufactured, packaged, and labeled
in accordance with the Product specifications, (ii) shall be manufactured in
accordance with quality system regulations (QSRs) under the Act and consistent
with other International Regulatory Standards such as ISO and the requirements
necessary to obtain and maintain CE Marking, (iii) are free from defects in
material and workmanship, and (iv) based on the advice of outside patent
counsel, do not infringe any third party intellectual property rights.

         (b) Specification Changes. If either party finds it necessary or
desirable to change any Product specifications including the materials used to
manufacture the Product, the manufacturing process thereof or protocols then in
effect for the Products, it shall request such change in writing, and the
parties shall thereafter discuss such change on a timely basis. No such change
shall be put into effect except upon the mutual consent of the parties. Neither
party shall withhold consent unreasonably. Everest shall provide test results to
Guidant within 10 days of making any such changes to assure that the Products
meet specifications and compliance with QSRs or other appropriate regulations.
None of the Products shall be discontinued during the term of this Agreement
without Guidant's written consent.

<PAGE>

         (c) Regulatory Clearance. Everest represents, warrants and covenants
(i) that it has, and will continue to have and maintain throughout the term of
the Agreement all permits, approvals and authorizations, including, without
limitation, such approvals as may be required under the Act, to manufacture and
sell Products in accordance with the terms of this Agreement, and (ii) that the
submissions made by Everest to obtain the necessary and appropriate permits,
approvals and authorizations were made in good faith and contained accurate data
and information regarding the Product as required by applicable laws, rules and
regulations. Everest shall notify Guidant as soon as practicable after receiving
notice of any claim or action by the FDA or other regulating body with respect
to any violation of any applicable regulatory related laws, rules or
regulations.

         (d) Continuing Compliance. Everest shall comply with all present and
future statutes, laws, ordinances and regulations relating to the manufacture,
assembly and supply of the Product, including, without limitation, those
enforced or promulgated by the FDA (including compliance with QSRs), and any
other registration requirements which may be imposed on the manufacture of
medical devices.

         (e) Inspection Rights. Guidant shall have the right, upon ten (1 0)
business days notice and during business hours, to inspect Everest's production,
packaging and quality control facilities as well as Everest's records relating
to the Products to verify Everest's compliance with the manufacturing, quality
systems and procedures for the Products under this Agreement and the Act and any
other applicable rules or regulations. Everest agrees to undertake necessary
corrective action to mutually agreed upon audit items. Additionally, Everest
agrees to notify Guidant in writing of any regulatory inspection of Everest's
facility or subcontractor's facility that may impact Guidant's ability to sell
or distribute Products in accordance with this Agreement. Everest will inform
Guidant of any adverse findings from any regulatory inspection that may impact
Guidant's ability to sell or otherwise distribute Product within five (5) days
of such adverse findings.

         (f) Product Liability Insurance. Everest shall obtain and maintain
product liability insurance in respect of the Products in amount of not less
than $1 million per occurrence and in the aggregate with a maximum deductible
per occurrence of not more than $10,000 single limit for bodily injury, death,
illness, and property damage arising from the use, sale or other distribution of
the Products. Everest will provide Guidant with thirty (30) days prior written
notice in the event of policy cancellation or a material change in its terms or
provisions. Everest will deliver a certificate evidencing such insurance to
Guidant upon written request by Guidant.

         3. PURCHASE OF PRODUCTS.

         (a) Orders and Acceptance. All orders for Products submitted by Guidant
shall be initiated by purchase orders to Everest. Everest shall acknowledge such
purchase orders within five (5) business days of receipt of order to confirm
Everest's ability to supply Products to Guidant in accordance with the terms of
the purchase order. An order may initially be placed orally if a confirming
purchase order is received by Everest within ten business (10) days after the

<PAGE>

oral order. The terms and conditions set forth in this Agreement and the
purchase order shall be the controlling terms for the purchase of Products by
Guidant (a copy of which is attached as Exhibit B) notwithstanding any terms and
conditions that may be contained on any statement, shipping, invoice,
acceptance, bill of lading or other document delivered by Everest to Guidant. In
the event of any conflict in the terms of a purchase order and the terms of this
Agreement, the terms of this Agreement shall control. Guidant may inspect
Products at its facility. Guidant may, within fifteen (15) days after receipt of
Products, return nonconforming Products to Everest for credit, refund of the
purchase price or replacement at Guidant's option. Everest shall bear all costs
and risk of loss for such returned Product provided that Everest has provided
Guidant authorization to return such Products, which authorization shall not be
unreasonably withheld. Products shall be deemed nonconforming if Guidant
determines in its inspection that they fail to materially comply with the
Product specifications. Guidant has up to six months after date of receipt of
Products to reject Products that are nonconforming in any material respect to
the certification provided by Everest for such Products, excluding shipping
damage. All nonconforming Products returned to Everest for replacement shall be
replaced in-kind by Everest at no cost to Guidant within thirty (30) business
days. If Everest can demonstrate to Guidant's satisfaction that Products
rejected as nonconforming conform to the Product specifications within thirty
(30) days of Everest's receipt of such Products, then Guidant shall issue a new
purchase order and accept the return of the Products.

         (b) Price. The price for each Product shall be an amount equal to two
(2) times Everest's material, labor and sterilization costs (the "Product
Costs"). Guidant shall have the right, on five (5) business days written notice
to Everest and at Guidant's expense, to audit the Product Costs used in
determining the price. The Product pricing will be reviewed jointly by Everest
and Guidant for each of the first two quarters following the introduction of any
Product, and twice per year thereafter. Appropriate adjustments, if any, shall
be made to the price and price ceiling following such reviews. The initial
prices for the Products are set forth on Exhibit A. In addition, either party
may request a Product price adjustment at anytime in the event that any design
changes approved by Guidant result in an increase or a decrease of $.50 or more
in the Product Costs.

         Everest agrees that in no event will the prices for the Products go
above the price ceilings for the Products identified on Exhibit A, unless design
specifications or volumes dictate such changes and are mutually agreed to.
Everest agrees that during the term of this Agreement that it will not offer the
co-exclusive Products to any third party at prices that are equal to or less
than the price offered to Guidant, unless that third party is purchasing a
higher volume of Products than Guidant, measured over the most recent two
calendar quarter period.

         (c) Payment. Payment shall be on a net thirty (30) day basis from the
date of Guidant's receipt of Products and an invoice for those products.

<PAGE>

         (d) Product Warranty Remedy. If any Products breach any of the Everest
representations or warranties contained in this Agreement, Everest shall, at
Guidant's election, replace the same or refund the purchase price, and reimburse
Guidant for its reasonable return freight incurred therefor.

         (e) Forecast and Minimum Requirements. Upon commencement of this
Agreement Guidant shall provide Everest with a monthly forecast of its
requirements for products for a one-year period. Guidant shall provide Everest
with an updated twelve month rolling forecast during the first quarter of each
new calendar quarter. Guidant shall provide Everest with blanket purchase orders
that cover at least nine future months from the date of issuance and shall place
new additional purchase orders, or add to existing purchase orders, at least
three months before the prior purchase order expires. These purchase orders will
specify monthly delivery quantities Guidant shall purchase all Product scheduled
for delivery on a three month rolling basis. Guidant may increase or decrease
scheduled delivery quantities beyond three months by up to 25% of the amounts
previously forecast or covered in a blanket purchase order. Everest shall use
commercially reasonable efforts to satisfy Guidant orders for Products in excess
of the forecasts.

         Guidant's minimum purchase requirements (the "Minimum Purchase
Requirements") for each of calendar years 2000-2003 are set forth on Exhibit A.
During the term of this Agreement (including any renewal term as provided in
Section 7), the parties agree to negotiate in good faith the Minimum Purchase
Requirement for the following year prior to the beginning of that year. The
parties agree that such negotiations shall be based upon the following and other
similar factors: (a) the previous years' Minimum Purchase Requirement; (b) the
competitive marketplace for the Products, including any recent changes, such as
the introduction of competitive products; and (c) any changes in the market
price(s) for the Products and competitive products. Further, unless the parties
otherwise agree, the Minimum Purchase Requirement for each such year shall be no
less than 50% nor more than 1.50% of the greater of the previous year's Minimum
Purchase Requirement or the number of units actually sold to Guidant for
distribution in the previous year.

         (f) Shipping. Guidant shall provide Everest with a minimum lead-time of
ninety (90) days from Everest's receipt of a purchase order to ship the
Products. In the event that a shorter lead time is requested by Guidant, Everest
shall use commercially reasonable efforts to meet the requested lead-time. All
Products delivered pursuant to the terms of this Agreement shall be suitably
packaged for shipment in appropriate shipping cartons, which, (i) in the case of
the Products identified as "Rigid Shaft Instruments" on Exhibit A (the "Rigid
Shaft Instruments"), shall mean individualized, sterile units, five (5) per box,
and (ii) in the case of the Products identified as "Flexible Shaft Instruments"
on Exhibit A (the "Flexible Shaft Instruments") shall mean non-sterile bulk
packaged. The Products shall be marked for shipment to Guidant's address set
forth above, and delivered to Guidant or its carrier agent F.O.B. Everest's
dock, at which time title to such Products and risk of loss shall pass to

<PAGE>

Guidant. Unless otherwise instructed in writing by Guidant, Guidant shall select
the carrier. All freight, insurance, and other shipping expenses shall be
charged directly to Guidant's shipping account.

         4. SALE OF THE PRODUCTS.

         (a) Co-Exclusivity and Exclusivity. During the first two years of this
Agreement, Everest agrees to sell the Rigid Shaft Instruments co-exclusively to
Guidant within the Field and the Territory. "Co-exclusively" means that only
Guidant and not more than one other party (which includes Everest if it is
distributing those products to any end-users of the Products) shall be entitled
to distribute those Products. In addition, during the first two years of this
Agreement, Everest agrees that is will sell the Flexible Shaft Instruments
exclusively to Guidant within the Field and the Territory. Following the first
two years of this Agreement, if Guidant continues to purchase Products at a rate
of at least fifteen thousand (15,000) units of Products (measured over the most
recently completed four calendar quarter period), Everest will continue to sell
the Products either co-exclusively or exclusively to Guidant as described in
this Section.

         (b) Trademarks, Labeling and Literature. Everest hereby grants to
Guidant a nonexclusive, royalty-free license to use the trademarks, trade names
and logos used by Everest to identify the Products (the "Trademarks") solely in
the course of Guidant's advertisement, promotion, distribution and sale of the
Products as provided in this Agreement. Use of the Trademarks on the Products
shall not give Guidant any proprietary rights in the Trademarks. Guidant shall
have the right to label the Flexible Shaft Instruments distributed under this
Agreement solely with Guidant's label, and to label the rigid Shaft Instruments
with both the Guidant and Everest Trademarks. Upon Guidant's request, Everest
shall furnish Guidant, without charge (except as otherwise agreed), with limited
samples of technical, advertising and selling information and literature
concerning the Products, provided that Everest has such materials available.
Guidant will remain primarily responsible for creating marketing materials for
the Products sold by Guidant under this Agreement.

         5. CONFIDENTIALITY. During the term of this Agreement and for a period
of five (5) years thereafter, Everest and Guidant shall maintain the disclosing
party's Confidential Information in confidence and will not disclose the same to
any person or entity not a party hereto or use the same for its respective
benefit or the benefit of any such third party except as may be necessary to
carry out the transactions contemplated by this Agreement. Everest and Guidant
will keep and maintain complete and accurate written records of the disclosing
party's Confidential Information, mark same with such legends as the disclosing
party may reasonably direct, and promptly deliver same to the disclosing party
upon written request upon the expiration or termination hereof or at such other
times as the disclosing party may request, except that in any such event,
counsel for the receiving party may retain one copy thereof solely for use
should any dispute between the parties arise. In addition, both during the term
and after the expiration or termination of this Agreement, Everest and Guidant
shall take such other reasonable actions as the disclosing party may request, at

<PAGE>

the disclosing party's expense, to enable the disclosing party to publish,
protect by litigation or otherwise, or further its title to any of its
Confidential Information.

         6. INDEMNIFICATION.

         (a) By Everest. Everest shall defend, indemnify, and hold Guidant
harmless from and Everest shall defend or settle, any claim, proceeding or suit
("Claim") against Guidant or its customers, to the extent arising out of a
breach of any warranty set forth in paragraph 2(a), excluding misrepresentation
of the product's labeling by a Guidant employee or agent, provided that such
obligation shall not extend to Claims related to use of the Product to the
extent that the claim is due to the fact that the Product is incorporated into
another product. Everest shall have sole control of any action or settlement and
shall pay any final judgment entered against Guidant or its customers on such
issue in any Claim. At Everest's request, Guidant shall provide Everest with
assistance (subject to Everest's reimbursement of Guidant's reasonable expenses
in providing such assistance) to defend or settle such Claim.

         (b) By Guidant. Guidant shall defend, indemnify, and hold Everest
harmless from and Guidant shall defend or settle, any Claim against Everest (i)
for infringement of any intellectual property right of any third party arising
from the sale or other distribution or use of any product that incorporates the
Product, or arising from any instructions, protocols or specifications provided
by Guidant to Everest, except to the extent such Claim is for infringement by
any Product, and (ii) arising from personal or bodily injury or death to the
extent arising out of the use of a product incorporating a Product, except to
the extent such Product failed to satisfy the warranty in Section 2(a) of this
Agreement. Guidant shall have sole control of any action or settlement and shall
pay any final judgment entered against Everest on such issue in any Claim.
Everest shall provide Guidant with assistance (subject to Guidant's
reimbursement of Everest's reasonable expenses in providing such assistance) to
defend or settle such Claim.

         (c) Individual Responsibility. Each of the parties shall be responsible
for its own errors and omissions and indemnifies, and agrees to hold harmless,
the other and its officers, directors, professional staff, employees, and
agents, and any of their respective affiliates, respective successors, heirs and
assigns (the "Indemnitees"), against any Claim incurred by or imposed upon the
Indemnitees to the extent arising out of the indemnifying party's own activities
hereunder (including actions in tort, warranty or strict liability), to the
extent that it is held by a court of competent jurisdiction (in a proceeding in
which the indemnifying party is a party) to be due to the indemnifying party's
activities hereunder, except as to claims covered under Section 6(a) or (b)
above. Each of the parties shall notify the other promptly of any claim, demand,
suit or action arising out of any activity hereunder, whether or not the subject
of the indemnity herein.

<PAGE>

         7. TERM. The initial term of this Agreement shall continue until
December 31, 2003, and shall continue thereafter for successive renewal terms of
one (1) year each unless and until terminated in writing in accordance with
Section 8(a).

         8. TERMINATION.

         (a) Termination at the End of a Term. Either party may terminate this
Agreement effective upon the end of the initial term or any extended term by
providing six (6) months advance notice in writing of its intent to terminate
this Agreement at the end of the applicable term.

         (b) Termination for Cause. Upon Everest's or Guidant's default in the
observance or performance of any material term or provision of this Agreement,
the other party shall have the right to give that party written notice thereof,
and that party shall then have thirty (30) days to cure the same. If such breach
or default is so cured within the thirty (30) day period, then this Agreement
shall remain in full force and effect. If the breach or default is not cured
within such thirty (30) day period, then this Agreement shall terminate at the
end of such cure period.

         (c) Termination by Everest. Everest may terminate this Agreement if
Guidant fails during any calendar year, to purchase the agreed upon Minimum
Purchase Requirements for that year. Prior to any such termination, Everest will
notify Guidant in writing of its failure to satisfy the Minimum Purchase
Requirements and the amount of additional Products that Guidant would need to
purchase to satisfy the Minimum Purchase Requirements (the "Shortfall"). Guidant
will have thirty (30) days from the date of Everest's notice in which to (i)
purchase an amount of Products equal to the Shortfall, (ii) pay Everest an
amount equal to one (1) times the Product Cost for the Shortfall, or (iii) any
combination of (i) and (ii). If Guidant cures the failure to satisfy the Minimum
Purchase Requirements as described in the preceding sentence, then the Agreement
will continue in full force and effect. Otherwise the Agreement will terminate
at the end of the thirty (30) day period following Everest's notice to Guidant.
Everest's sole remedy for Guidant's failure to purchase the minimum requirements
shall be termination of this Agreement as provided in this Section 8(c).

         (d) Termination by Guidant Without Cause Following Significant
Corporate Event. Guidant may terminate this Agreement at anytime by providing
Everest thirty (30) days advance written notice of its intent to terminate this
Agreement if Everest (i) merges with a third party, sells all or substantially
all of its assets or stock, or a change in control of Everest occurs, or (ii)
announces that it has entered into an agreement to transact one of the events
described in Subsection 8(d)(i). If Guidant terminates this Agreement pursuant
to this Section 8(d), Guidant will have the right to make a final purchase of
Products in an amount equal to up to its current twelve month forecast for the
Products, and Everest will use commercially reasonable efforts to supply
Products for such final purchase as soon as practicable after such order is
placed.

<PAGE>

         (d) Termination for Insolvency. This Agreement shall terminate, without
notice, (i) upon the institution by or against either party of insolvency,
receivership or bankruptcy proceedings or any other proceedings for the
settlement of the insolvent party's debts, (ii) upon the insolvent party making
an assignment for the benefit of creditors, or (iii) upon the insolvent party's
dissolution or ceasing to do business.

         9. WAIVER. The failure of Everest or Guidant to exercise any right
under this Agreement shall not prevent such party from exercising such or any
other right at a later time.

         10. EXCLUSIVENESS OF REMEDIES. Except as otherwise provided herein, all
rights accorded either of the parties hereunder shall be cumulative of all other
rights so granted as well as any rights and remedies either of them may have at
law or in equity.

         11. SURVIVAL. All representations or warranties made hereunder, and all
terms and provisions intended to be observed and performed after the expiration
or termination hereof, shall survive such expiration or termination and continue
in full force and effect.

         12. NOTICES. All notices or other communications required or permitted
to be given under this Agreement shall be in writing and will be deemed
effective and given when (i) delivered in person, (ii) sent by facsimile with
confirmation of receipt, or (iii) actually received if sent by certified or
registered mail, postage and certification prepaid. All notices shall be sent to
a party at its address first set forth above, attention President, or such other
address as the party shall provide to the other party.

         13. ASSIGNMENT. This Agreement may not be assigned by either Everest or
Guidant without the prior written consent of the other, which consent will not
be unreasonably delayed or withheld, except that either party may assign this
Agreement, with written notice to the other party, but without its consent, to a
purchaser of all or substantially all of that portion of that party's business
to which this Agreement relates. In the event this Agreement is assigned, the
assignee shall be bound to all of the terms and conditions of this Agreement.

         14. SUCCESSORS. This Agreement shall be binding upon and inure to the
benefit of Everest and Guidant and their respective successors and permitted
assigns.

         15. PUBLICITY. Neither party shall originate any publicity, news
release or other announcement, written or oral, whether to the public or press,
to stockholders or otherwise, relating to this Agreement, to any amendment
hereto or to performance hereunder without the prior written consent of the
other, except as may be required, in the judgment of either parties legal
counsel, to comply with the requirements of any applicable law, including, but
not limited to, any disclosures required by state or federal securities laws.

<PAGE>

         16. GOVERNING LAW, JURISDICTION AND VENUE. This Agreement shall be
governed by and construed in accordance with the laws of the State of California
as applied to agreements entered into and performed entirely within California
between California residents. The parties consent and submit to the exclusive
jurisdiction and venue of the courts located in and serving San Mateo,
California in any litigation arising out of this Agreement.

         17. INVALIDITY. The invalidity or unenforceability of any term or
provision of this Agreement shall not affect the other terms and provisions, and
such invalid or unenforceable term or provision will, in all events, be
construed and enforced to the fullest extent permissible under applicable law.

         18. ENTIRE AGREEMENT. This Agreement and any Guidant purchase order
contain the entire agreement between the parties hereto regarding the sale of
the Products, and no other promises, agreements, or warranties, written or
verbal, shall be of any force or effect. No modification of this Agreement shall
be of any force or effect unless such modification is in writing, refers
specifically to this Agreement, contains language indicating it is a
modification to this Agreement, and is signed by the party alleged to be bound
thereby.

         19. SECTION HEADINGS. The section headings included in this Agreement
are for reference purpose only and shall not affect the meaning or
interpretation of this Agreement.

         20. FORCE MAJEURE. Nonperformance of either party shall be excused to
the extent that performance is rendered impossible by strike, fire, flood,
governmental act or orders or restrictions or any other reason where failure to
perform is beyond the reasonable control of and is not caused by the negligence
of the nonperforming party. Whenever Everest's performance is delayed or
prevented for any reason in accordance with the foregoing, Everest shall
promptly notify Guidant of the existence thereof and of the expected duration
and the estimated effect thereof upon its ability to perform its obligations.

         IN WITNESS WHEREOF, the parties have caused their duly authorized
representatives to execute this Agreement in duplicate on the date first above
written.

EVEREST MEDICAL CORPORATION                    GUIDANT CORPORATION

By:     /s/ John L. Shannon, Jr.               By:  /s/ F. Thomas Watkins

Title:  President & chief Executive Officer    Title:   Vice President

<PAGE>

                                    EXHIBIT A

                      PRODUCTS, PRICES AND ANNUAL FORECAST

<PAGE>

                                    EXHIBIT B

                          GUIDANT PURCHASER ORDER FORMExhibit 10.1

NEWS BULLETIN                           RE:      NOBLE ROMAN'S, INC.
                                                 1 Virginia Avenue, Suite 800
                                                 Indianapolis, IN  46204

FOR ADDITIONAL INFORMATION, CONTACT:

               Paul W. Mobley, Chairman
                      317/634-3377
           Michael Lauren, Investor Relations
                      415/564-5677

Indianapolis, Indiana - Noble Roman's, Inc. announced today that in a series of
transactions which closed on February 8, 2000, it has obtained approximately
$8.5 million in additional capital. These events are part of its strategic plan
to position Noble Roman's for accelerated growth in the franchising of
non-traditional locations and co-branding with other traditional foodservice
companies such as Subway(R) and TCBY(R).

Noble Roman's, Inc. began franchising non-traditional locations in 1997, and
co-branding with Subway and TCBY in 1999. To date the company has awarded over
500 franchised locations in 35 states with many more on the way. Though
non-traditional locations were developed first, officials at Noble Roman's
anticipate co-branding will offer at least as much if not more opportunity for
growth in the future.

Over the past two years the company has developed a method for franchisees to
establish a miniaturized version of a Noble Roman's pizzeria in universities,
recreational facilities, convenience stores, travel plazas and other
high-traffic facilities. These "non-traditional" locations, as they are called,
offer many of the same quality menu items that Noble Roman's has sold for 28
years at its traditional locations, including fresh made pizzas and breadsticks
among other items, plus a line of breakfast products. In discussing the
company's non-traditional franchise concept, Paul Mobley, Chairman of Noble
Roman's, stated, "We believe our concept is second to none. The food quality is
superior, the operations are simple, staffing requirements are minimal, and the
franchisee gets the benefit of a low initial investment and great on-going unit
economics. So far we have received an amazing reception in 35 states, and the
growth possibilities are enormous".

In addition to the non-traditional locations, the company has franchised
locations under co-branding agreements such as the recent opening of Noble
Roman's franchises in the TCBY at 49th Street and Pennsylvania Avenue and in the
Subway at West 71st Street and I-465, both in Indianapolis. Scott Mobley,
President of Noble Roman's, stated that, "Both non-traditional and co-branded
franchising are the wave of the future in the restaurant industry, and we're on
the cutting edge of that trend. We developed what we think is a better concept,
and this fact has been proven in the rapid sale of more than 500 franchises in
just over 2 years. We are devoting as much of our human resources as possible to
capitalize on this early success."

<PAGE>

Accordingly, the company will now limit its direct operational involvement in
traditional locations to a core group of locations in the Indianapolis,
Columbus, Bloomington and Evansville area markets in Indiana. Scott Mobley said,
"We have closed 16 traditional locations at least temporarily while we complete
on-going discussions on the possibility of re-opening them as franchises or
co-brand locations. In the meantime, we have reassigned several supervisors and
others formerly involved in those operations to help facilitate the growth of
our non-traditional and co-branded facilities. But the traditional locations are
extremely important to us - our product innovations and operating experience all
come from that side of the business, and we expect they will continue to do so
in the future."

The additional capital came from investors associated with Geometry Group, Inc.
in New York, certain local investors in Indianapolis and The Provident Bank in
Cincinnati. The Geometry Group and other local investors purchased common stock
of the company for approximately $2.0 million in a private placement. The
Provident Bank exchanged $6.5 million senior secured debt for $1.6 million in
common stock and $4.9 million in no-yield preferred stock which may later be
converted to common stock at $3.00 per share at its option.

Paul Mobley stated that, "Having already begun to reap the rewards of a
repositioned business strategy, and now with the significant increase in capital
and the management infrastructure which has been established in the past two
years, Noble Roman's is positioned for the expansion of several thousand
franchised co-branded and non-traditional units over the next few years." Mobley
further stated, "I am extremely pleased with the way Noble Roman's is now
positioned for the future. We have aligned our company with several of the
largest and well known retail food establishments in the country including
Subway(R) and TCBY(R). As experts in the field of food retailing both of these
companies recognize the significance of co-branding and have chosen Noble
Roman's over hundreds of other concepts. There is no doubt that co-branding and
non-traditional fast food retailing are sweeping the nation as more and more of
us eat where it is convenient. Given this need for consumer convenience, we
believe our business strategy has positioned Noble Roman's to take advantage of
these opportunities."

Given the significance of the current transactions, the company will be filing a
Form 8-k with the SEC showing restated proforma income statement information as
if the transactions had occurred on January 1, 1998, and proforma balance sheet
information as if the transactions had occurred on September 30, 1999. The
proforma income statement shows operations at approximately a break-even level
for both the twelve months ended December 31, 1998 and the nine months ended
September 30, 1999. The proforma balance sheet as of September 30, 1999 shows
current assets of $4.0 million (actual September 30, 1999 were $2.9 million),
current liabilities of $3.3 million (actual current liabilities for September
30, 1999 were $4.0 million), long-term obligations of $10.6 million (actual
September 30, 1999 were $16.7 million) and stockholder's equity of $4.6 million
(actual September 30, 1999 were $17 thousand).

The statements contained in this Press Release concerning the Company's future
revenues, profitability, financial resources, market demand and product
development are forward-looking statements (as such term is defined in the
Private Securities Litigation Reform Act of 1995) relating to the Company that
are based on the beliefs of the management of the Company, as well

<PAGE>

as assumptions and estimates made by and information currently available to the
Company's management. The Company's actual results in the future may differ
materially from those projected in the forward-looking statements due to risks
and uncertainties that exist in the Company's operations and business
environment including, but not limited to: the operations and results of
operations of the Company as well as its customers and suppliers, including as a
result of competitive factors and pricing pressures, shifts in market demand,
general economic conditions and other factors including but not limited to,
changes in demand, for the Company's products or franchises, the impact of
competitors' actions, and changes in prices or supplies of food ingredients.
Should one or more of these risks or uncertainties materialize, or should
underlying assumptions or estimates prove incorrect, actual results may vary
materially from those described herein as anticipated, believed, estimated,
expected or intended.

                                    - END -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]